Published in J Plast Reconstr Aesthet Surg on November 18, 2009
Awareness and Perception of Plastic Surgery among Healthcare Professionals in Pune, India: Do They Really Know What We Do? Plast Surg Int (2012) 1.92
Undergraduate plastic surgery education: problems, challenges, and proposals. Ann Med Health Sci Res (2014) 1.42
Re: Davis et al. How to improve plastic surgery knowledge, skills and career interest in undergraduates in one day. JPRAS 2010:63;1677-1681. J Plast Reconstr Aesthet Surg (2010) 1.12
Basic Plastic Surgery Skills Training Program on Inanimate Bench Models during Medical Graduation. Plast Surg Int (2012) 0.91
Developing undergraduate interest in plastic surgery. J Plast Reconstr Aesthet Surg (2011) 0.81
A multi-specialty surgical course for residents transitioning from early to intermediate training. Int J Med Educ (2016) 0.75
Is the current UK undergraduate system providing junior doctors knowledge and confidence to manage burns? A questionnaire-based cohort study. Burns Trauma (2015) 0.75
Reconstruction of facial defects with local flaps--a training model for medical students? Head Face Med (2015) 0.75
Plastic Surgery Inclusion in the Undergraduate Medical Curriculum: Perception, Challenges, and Career Choice-A Comparative Study. Plast Surg Int (2017) 0.75
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Cross-cultural primary care: a patient-based approach. Ann Intern Med (1999) 5.06
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol (1970) 4.48
Analysis of vertebrate SCL loci identifies conserved enhancers. Nat Biotechnol (2000) 4.01
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Laparoscopic cholecystectomy: potential for missed pathology. Ann R Coll Surg Engl (1994) 3.03
Ecstasy and neurodegeneration. BMJ (1996) 2.93
Total synthesis of a human leukocyte interferon gene. Nature (1981) 2.76
Eikenella corrodens, a recently recognized pathogen: infections in medical-surgical patients and in association with methylphenidate abuse. Medicine (Baltimore) (1974) 2.61
The SCL gene specifies haemangioblast development from early mesoderm. EMBO J (1998) 2.47
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol (1972) 2.05
Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res (2001) 2.04
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol (2005) 1.96
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat (2011) 1.74
Analysis of pineal and brain indole alkylamines by gas chromatography-mass spectrometry. Adv Biochem Psychopharmacol (1973) 1.71
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature (1968) 1.69
An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development (1999) 1.67
The SCL gene: from case report to critical hematopoietic regulator. Blood (1999) 1.65
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol (2009) 1.60
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood (2000) 1.58
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology (2007) 1.57
Cephalosporin-induced immune neutropenia. Br J Haematol (1985) 1.56
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer (1998) 1.51
Experimental pneumococcal meningitis. II. Characterization and quantitation of the inflammatory process. J Infect Dis (1975) 1.49
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
Environmental impacts and sustainability of egg production systems. Poult Sci (2011) 1.46
The use of the latissimus dorsi musculocutaneous flap for immediate correction of the deformity resulting from breast conservation surgery. Br J Plast Surg (1999) 1.45
A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1985) 1.43
Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol (2011) 1.41
The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochem Pharmacol (1970) 1.41
Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev Biol (1999) 1.41
The use of a silicone flexor tendon as a teaching model for flexor tendon repair: a clear view. J Plast Reconstr Aesthet Surg (2012) 1.39
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development (2001) 1.37
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol (1995) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke (2009) 1.32
Molecular cloning and chromosomal localization of the murine homolog of the human helix-loop-helix gene SCL. Proc Natl Acad Sci U S A (1991) 1.32
The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology (1985) 1.30
Hypertension in multicultural and minority populations: linking communication to compliance. Curr Hypertens Rep (1999) 1.28
The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci U S A (1993) 1.28
Prospective evaluation of late cosmetic results following breast reconstruction: I. Implant reconstruction. Plast Reconstr Surg (2001) 1.27
Letter: Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature (1975) 1.27
Epidemiology of burns in childhood. Burns Incl Therm Inj (1984) 1.27
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Lineage-restricted regulation of the murine SCL/TAL-1 promoter. Blood (1995) 1.25
3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) (2001) 1.22
Prevention of nosocomial influenza infection with Amantadine. Am J Epidemiol (1973) 1.21
Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system. Proc Natl Acad Sci U S A (1992) 1.21
Regulation of the stem cell leukemia (SCL) gene: a tale of two fishes. Proc Natl Acad Sci U S A (2001) 1.20
Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol (1997) 1.17
Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat (2011) 1.17
Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo. Mol Cell Biol (2005) 1.16
Necrotising fasciitis of the breast. Br J Plast Surg (2001) 1.15
In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol (1997) 1.14
The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol (1995) 1.13
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat. Br J Pharmacol (1994) 1.13
The SCL +40 enhancer targets the midbrain together with primitive and definitive hematopoiesis and is regulated by SCL and GATA proteins. Mol Cell Biol (2007) 1.13
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. J Biol Chem (1997) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11
5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol (1993) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Alterations in GABA metabolism and Met-enkephalin content in rat brain following repeated electroconvulsive shocks. J Neurochem (1978) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood (1994) 1.10
The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. Neuropharmacology (1986) 1.09
The spectrum of tuberculous peritonitis. Chest (1977) 1.09
The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology (1998) 1.09
Waiting in the emergency room: how to improve patient satisfaction. J Health Care Mark (1993) 1.08
Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther (2009) 1.08
MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol (2009) 1.08
NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke (2001) 1.08
Effects of intracranial dopamine perfusion: behavioural arousal and reversal of cerebral arterial spasm following surgery for clipping of ruptured cerebral aneurysms. Proc R Soc Med (1977) 1.08
Regional rat brain benzodiazepine receptor number and gamma-aminobutyric acid concentration following a convulsion. Br J Pharmacol (1982) 1.07
Transcriptional regulation of the stem cell leukemia gene by PU.1 and Elf-1. J Biol Chem (1998) 1.06
Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol (2002) 1.06
Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol (1991) 1.06
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05
Studies on the post-ictal rise in seizure threshold. Eur J Pharmacol (1981) 1.05
Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol (1998) 1.05
Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA. Br J Pharmacol (1976) 1.05
Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol (1994) 1.04
The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat. Neuroscience (1993) 1.04